Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity

Sabrina Wimmer ^1,2 * , Sarai M. Keestra ^3,4

Cited by CrossRef:

1- Perehudoff K, Wirtz V, Wong A, Rusu V, Kohler J. A global social contract to ensure access to essential medicines and health technologies. BMJ Glob Health. 2022;7(11):e010057 [Crossref]

2- Cross S, Rho Y, Reddy H, Pepperrell T, Rodgers F, Osborne R, Eni-Olotu A, Banerjee R, Wimmer S, Keestra S. Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?. BMJ Glob Health. 2021;6(12):e007321 [Crossref]

3- Keestra S, Rodgers F, Osborne R, Wimmer S. University patenting and licensing practices in the United Kingdom during the first year of the COVID-19 pandemic. Global Public Health. 2022;17(5):641 [Crossref]

4- Bilić P, Prug T. Google’s Post-IPO Development: risks, rewards, and shareholder value. Internet Histories. 2021;5(2):171 [Crossref]

Submit Your Paper Archive